SEC Form 424B3 filed by Yield10 Bioscience Inc.
![[MISSING IMAGE: lg_yield10bioscience-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0001121702/000110465924083521/lg_yield10bioscience-4c.jpg)
SECTION ENTITLED “RISK FACTORS” BEGINNING ON PAGE 7.
approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.
| | | | | 1 | | | |
| | | | | 5 | | | |
| | | | | 7 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 12 | | | |
| | | | | 14 | | | |
| | | | | 15 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 19 | | |
Warrants
| | |
Years Ended December 31,
|
| |||||||||
(in thousands, except share and per share amounts)
|
| |
2023
|
| |
2022
|
| ||||||
Net loss
|
| | | $ | (14,455) | | | | | $ | (13,566) | | |
Basic and diluted net loss per share
|
| | | $ | (1.82) | | | | | $ | (2.76) | | |
Number of shares used in per share calculations (basic and diluted)
|
| | | | 7,946,281 | | | | | | 4,914,565 | | |
Shares of common stock outstanding at year end
|
| | | | 12,032,425 | | | | | | 4,944,202 | | |
| | |
Shares
|
| |
Par Value
|
| ||||||
Balance, December 31, 2021 (in thousands, except share and per share amounts)
|
| | | | 4,881,851 | | | | | $ | 49 | | |
Issuance of common stock for 401(k) match
|
| | | | 36,706 | | | | |
|
—
|
| |
Issuance of common stock upon vesting of restricted stock units
|
| | | | 25,645 | | | | |
|
—
|
| |
Balance, December 31, 2022
|
| | | | 4,944,202 | | | | | $ | 49 | | |
Issuance of common stock for 401(k) match
|
| | | | 119,971 | | | | | | 1 | | |
Issuance of common stock under At-the-Market offering, net of issuance costs
|
| | | | 94,665 | | | | | | 1 | | |
Issuance of common stock upon vesting of restricted stock units
|
| | | | 17,640 | | | | | | — | | |
Issuance of common stock and warrants in equity offerings, net of issuance
costs |
| | | | 6,756,710 | | | | | | 68 | | |
Issuance of common stock for director compensation
|
| | | | 99,237 | | | | | | 1 | | |
Balance, December 31, 2023
|
| | | | 12,032,425 | | | | | | 120 | | |
| | |
Years Ended December 31,
|
| |||||||||
Unaudited (in thousands, except share and per share amounts)
|
| |
2023
|
| |
2022
|
| ||||||
Net loss
|
| | | $ | (14,455) | | | | | $ | (13,566) | | |
Basic and diluted net loss per share
|
| | | $ | (43.66) | | | | | $ | (66.25) | | |
Number of shares used in per share calculations (basic and diluted)
|
| | | | 331,101 | | | | | | 204,780 | | |
Shares of common stock outstanding at year end
|
| | | | 501,357 | | | | | | 206,015 | | |
| | |
Shares
|
| |
Par Value
|
| ||||||
Balance, December 31, 2021 (Unaudited, in thousands, except share and per share amounts)
|
| | | | 203,417 | | | | | $ | 2 | | |
Issuance of common stock for 401(k) match
|
| | | | 1,529 | | | | |
|
—
|
| |
Issuance of common stock upon vesting of restricted stock units
|
| | | | 1,069 | | | | |
|
—
|
| |
Balance, December 31, 2022
|
| | | | 206,015 | | | | | $ | 2 | | |
Issuance of common stock for 401(k) match
|
| | | | 4,998 | | | | | | — | | |
Issuance of common stock under At-the-Market offering, net of issuance costs
|
| | | | 3,945 | | | | | | — | | |
Issuance of common stock upon vesting of restricted stock units
|
| | | | 735 | | | | | | — | | |
Issuance of common stock and warrants in equity offerings, net of issuance costs
|
| | | | 281,530 | | | | | $ | 3 | | |
Issuance of common stock for director compensation
|
| | | | 4,131 | | | | | | — | | |
Balance, December 31, 2023
|
| | | | 501,357 | | | | | $ | 5 | | |
| | |
Prior to the Offering
|
| | | | | | | |
After the Offering
|
| ||||||||||||||||||
Selling Security Holder(1)
|
| |
Number of Shares
of Common Stock Beneficially Owned(2) |
| |
Percent of
Common Stock Outstanding(3) |
| |
Maximum Number
of Shares of Common Stock Being Registered for Resale |
| |
Number of
Shares of Common Stock Beneficially Owned(4) |
| |
Percent of
Common Stock Outstanding(3)(4) |
| |||||||||||||||
Armistice Capital Master Fund Ltd.(5)
|
| | | | 230,142 | | | | | | 28.9% | | | | | | 153,428 | | | | | | 76,714 | | | | | | 11.9% | | |
Brio Capital Master Fund Ltd.(6)
|
| | | | 45,410 | | | | | | 6.8% | | | | | | 29,167 | | | | | | 16,243 | | | | | | 2.5% | | |
L1 Capital Global Opportunities Master Fund(7)
|
| | | | 22,916 | | | | | | 3.5% | | | | | | 8,333 | | | | | | 14,583 | | | | | | 2.2% | | |
Lind Global
Fund II LP(8) |
| | | | 62,500 | | | | | | 9.1% | | | | | | 41,667 | | | | | | 20,833 | | | | | | 3.2% | | |
S.H.N. Financial Investments Ltd.(9)
|
| | | | 50,000 | | | | | | 7.4% | | | | | | 33,333 | | | | | | 16,667 | | | | | | 2.6% | | |
Total | | | | | | | | | | | | | | | | | 265,928 | | | | | | | | | | | | | | |
Yield10 Bioscience, Inc.
19 Presidential Way
Woburn, MA 01801
(617)583-1700
![[MISSING IMAGE: lg_yield10bioscience-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0001121702/000110465924083521/lg_yield10bioscience-4c.jpg)